{
    "clinical_study": {
        "@rank": "112896", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive a maximum of 6 courses. Patients with partial response receive a maximum of 12 courses. Patients with CR receive 2 additional courses beyond CR."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of CCI-779 in treating patients who have mantle\n      cell non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer\n      cells from dividing so they stop growing or die."
        }, 
        "brief_title": "CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "February 2008", 
            "@type": "Actual"
        }, 
        "condition": "Recurrent Mantle Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the objective responses in patients with previously treated mantle cell\n      non-Hodgkin's lymphoma treated with CCI-779.\n\n      II. Determine the toxic effects of this drug in these patients. III. Determine whether this\n      drug inhibits cell proliferation pathways in these patients.\n\n      OUTLINE:\n\n      Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every\n      28 days in the absence of disease progression or unacceptable toxicity. Patients with stable\n      disease receive a maximum of 6 courses. Patients with partial response receive a maximum of\n      12 courses. Patients with complete response (CR) receive 2 additional courses beyond CR.\n\n      Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months\n      for 1 year, and then annually for 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed mantle cell non-Hodgkin's lymphoma (MCL)\n\n          -  Relapsed, refractory, or stable disease after prior chemotherapy, radiotherapy, or\n             immunotherapy\n\n          -  Unidimensionally measurable lymph node or lesion\n\n               -  At least 2.0 cm by CT scan or MRI OR at least 1.5 cm by physical exam\n\n               -  One of the following measurement parameters may be used:\n\n                    -  Splenic enlargement  may be used as a measurement parameter if spleen is\n                       palpable at least 3.0 cm across left   costal margin\n\n                    -  Malignant lymphocytosis may be used as a measurement parameter if absolute\n                       lymphocyte count is at least 5,000/mm^3\n\n          -  No known CNS involvement (parenchymal mass or leptomeningeal involvement)\n\n          -  Performance status - ECOG 0-2\n\n          -  At least 3 months\n\n          -  See Disease Characteristics\n\n          -  Absolute neutrophil count \u2265 1,000/mm^3\n\n          -  Platelet count \u2265 75,000/mm^3\n\n          -  Hemoglobin \u2265 8 g/dL\n\n          -  Total bilirubin \u2264 1.5 times upper limit of normal (ULN)\n\n          -  Direct bilirubin \u2264 1.5 times ULN\n\n          -  AST \u2264 3 times ULN (5 times ULN if liver metastases are  present)\n\n          -  Creatinine \u2264 2 times ULN\n\n          -  No symptomatic congestive heart failure\n\n          -  No unstable angina pectoris\n\n          -  No cardiac arrhythmia\n\n          -  Cholesterol \u2264 350 mg/dL\n\n          -  Triglycerides \u2264 400 mg/dL\n\n          -  HIV negative\n\n          -  No other active malignancy requiring treatment or that would preclude study\n             participation\n\n          -  No other concurrent uncontrolled  illness\n\n          -  No ongoing or active infection\n\n          -  No psychiatric illness or social situation that would preclude study participation\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception during and for 3 months  after\n             study participation\n\n          -  See Disease Characteristics\n\n          -  Prior high-dose therapy with stem cell transplantation allowed\n\n          -  At least 7 days since prior immunotherapy or other non-myelosuppressive  biologic\n             response modifiers\n\n          -  See Disease Characteristics\n\n          -  See Biologic therapy\n\n          -  At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas\n             or mitomycin)\n\n          -  No other concurrent chemotherapy for MCL\n\n          -  Concurrent corticosteroids for adrenal insufficiency allowed\n\n          -  See Disease Characteristics\n\n          -  At least 3 weeks since prior radiotherapy\n\n          -  No concurrent radiotherapy for MCL\n\n          -  Any number of prior treatments allowed\n\n          -  No other concurrent investigational or commercial agents for MCL\n\n          -  No concurrent drugs that induce cytochrome p450 (e.g., carbamazepine, phenobarbital,\n             phenytoin, ketoconazole, diltiazem, rifampin, terfenadine, cisapride, astemizole, or\n             pimozide)\n\n          -  No concurrent immunosuppressive therapies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 9, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00033267", 
            "org_study_id": "NCI-2012-01870", 
            "secondary_id": [
                "NCI-2012-01870", 
                "NCCTG-N0186", 
                "CDR0000069269", 
                "N0186", 
                "N0186", 
                "U10CA025224"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "description": "Given IV", 
            "intervention_name": "temsirolimus", 
            "intervention_type": "Drug", 
            "other_name": [
                "CCI-779", 
                "cell cycle inhibitor 779", 
                "Torisel"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "North Central Cancer Treatment Group"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of CCI-779 in Previously Treated Patients With Mantle Cell Non-Hodgkin's Lymphoma", 
        "overall_official": {
            "affiliation": "North Central Cancer Treatment Group", 
            "last_name": "Stephen Ansell", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The proportion will be evaluated separately for each dose group. The proportion of patients who achieve a confirmed CR or PR, or success, will be estimated by the number of successes divided by the total number of evaluable patients. Ninety-five percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.", 
            "measure": "Proportion of patients who achieve a confirmed CR or PR during the first 24 weeks of treatment defined by the International Workshop criteria", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00033267"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The distribution of time to progression will be estimated using the method of Kaplan-Meier.", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Time from registration to the time of progression, assessed up to 5 years"
            }, 
            {
                "description": "The distribution of overall survival will be estimated using the method of Kaplan-Meier.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Time from registration to death due to any cause, assessed up to 5 years"
            }, 
            {
                "description": "The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Time from registration to progression or death due to any cause, assessed up to 5 years"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "From the date of study registration until the date of progression in the subset of patients who respond, assessed up to 5 years"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }, 
    "geocoordinates": {
        "North Central Cancer Treatment Group": "44.022 -92.47"
    }
}